TARSUS PHARMACEUTICALS INC's ticker is TARS and the CUSIP is 87650L103. A total of 93 filers reported holding TARSUS PHARMACEUTICALS INC in Q2 2023. The put-call ratio across all filers is 0.20 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $5,586,876 | -24.6% | 205,551 | +0.9% | 0.00% | 0.0% |
| Q1 2024 | $7,405,586 | +54.0% | 203,730 | -14.2% | 0.00% | 0.0% |
| Q4 2023 | $4,808,140 | +170.4% | 237,439 | +137.3% | 0.00% | – |
| Q3 2023 | $1,778,102 | +27.9% | 100,062 | +30.0% | 0.00% | – |
| Q2 2023 | $1,390,523 | +287.3% | 76,952 | +169.4% | 0.00% | – |
| Q1 2023 | $359,062 | -56.0% | 28,565 | -48.7% | 0.00% | – |
| Q4 2022 | $816,092 | +43728.8% | 55,668 | -48.8% | 0.00% | – |
| Q3 2022 | $1,862 | +29.2% | 108,728 | +10.1% | 0.00% | – |
| Q2 2022 | $1,441 | -99.7% | 98,710 | +249.3% | 0.00% | – |
| Q1 2022 | $475,000 | -24.8% | 28,256 | +0.5% | 0.00% | – |
| Q4 2021 | $632,000 | +10.7% | 28,103 | +6.1% | 0.00% | – |
| Q3 2021 | $571,000 | -26.7% | 26,480 | -1.5% | 0.00% | – |
| Q2 2021 | $779,000 | -16.6% | 26,880 | -7.3% | 0.00% | – |
| Q1 2021 | $934,000 | – | 28,994 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 2,089,856 | $35,778,000 | 4.39% |
| Vivo Capital, LLC | 2,262,200 | $38,729,000 | 4.28% |
| Cormorant Asset Management, LP | 1,971,422 | $33,751,000 | 2.36% |
| Frazier Life Sciences Management, L.P. | 1,787,527 | $30,602,000 | 2.36% |
| Sands Capital Ventures, LLC | 260,000 | $4,451,000 | 1.29% |
| COWEN AND COMPANY, LLC | 522,329 | $8,942,000 | 0.86% |
| RTW INVESTMENTS, LP | 2,023,179 | $34,637,000 | 0.80% |
| Perceptive Advisors | 1,296,416 | $22,194,000 | 0.64% |
| Ghost Tree Capital, LLC | 120,000 | $2,054,000 | 0.58% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1,324,214 | $22,671,000 | 0.45% |